Maria Reig

Prof. Dr. Maria Reig

Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet
Verified
Journal Article
Closed access
AFAlejandro Forner
Alejandro Forner
MRMaria Reig
Maria Reig
JBJordi Bruix
Jordi Bruix

19 November 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
MRMaria Reig
Maria Reig
AFAlejandro Forner
Alejandro Forner
JRJordi Rimola
Jordi Rimola
JFJoana Ferrer-Fàbrega
Joana Ferrer-Fàbrega
MBMarta Burrel
Marta Burrel
JBJordi Bruix
Jordi Bruix

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JBJordi Bruix
Jordi Bruix
MRMaria Reig
Maria Reig
MSMorris Sherman
Morris Sherman

19 February 2010 in Seminars in Liver Disease
Verified
Journal Article
Closed access
AFAlejandro Forner
Alejandro Forner
MRMaria Reig
Maria Reig
CLCarlos Rodriguez de Lope
Carlos Rodriguez de Lope
JBJordi Bruix
Jordi Bruix
Staging and treatment indication are relevant topics in the management of patients with hepatocellular carcinoma (HCC) and for optimal results, they have to take into account liver function, tumor stage, and physical status. For any staging system to be meaningful it has to link staging with treatment indication; this should be based on robust scientific data. Currently, the sole proposal that serves both aims is the Barcelona Clinic Liver Cancer (BCLC) approach. It takes into account the relevant parameters of all important dimensions and divides patients into very early/early, intermediate, advanced, and end-stage. Early-stage HCC patients should be considered for potentially curative options such as resection, ablation, and transplantation. Patients at intermediate stage benefit from chemoembolization, whereas patients at an advanced stage, or who cannot benefit from options of higher priority, have sorafenib as the standard treatment. Finally, patients at end-stage should merely receive palliative care.

1 October 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
MRMaria Reig
Maria Reig
ZMZoe Mariño
Zoe Mariño
CPChristie Perelló
Christie Perelló
MIMercedes Iñarrairaegui
Mercedes Iñarrairaegui
ARAndrea Ribeiro
Andrea Ribeiro
JBJordi Bruix
Jordi Bruix

1 May 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
RLRiccardo Lencioni
Riccardo Lencioni
JLJosep M. Llovet
Josep M. Llovet
GHGuohong Han
Guohong Han
WTWon Young Tak
Won Young Tak
JYJiamei Yang
Jiamei Yang
JBJordi Bruix
Jordi Bruix